Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can Eye-Tracking reveal hidden brain risks in babies with sickle cell disease?

NCT ID NCT07721155

Knowledge-focused Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

Sickle cell disease can affect brain development even in very young children. This study uses eye-tracking—a simple, non-invasive method—to measure attention and processing speed in infants aged 6 to 24 months. The goal is to identify those at highest risk for cognitive challenges early, so that supportive interventions can be started sooner.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could enable early detection of cognitive problems in children with sickle cell disease, allowing for timely interventions to support brain development.
What could go wrong
This is an observational study, not a treatment trial. It may not directly improve outcomes, and eye-tracking may not fully capture complex cognitive abilities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

93 people

The number who actually took part.

Started

Mar 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Children between the 6 and 24 months are invited to participate in the study.

Ages

6 to 24 months

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 6 - 24 months old * Inhabitant of the Netherlands * Written informed consent from parent/caretaker. Exclusion Criteria: * Refused informed consent from parents/care-taker * Diagnosis of visual impairment (which cannot be corrected by glasses) * Diagnosis of a (co-morbid) congenital developmental condition * Any neurological condition, unrelated to SCD, that could affect the central nervous system, such as brain trauma, epilepsy and meningitis/encephalitis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neurocognition, child are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neurocognition, child Sickle cell Sickle cell disease

Contacts and locations

Locations

  • Amsterdam UMC

    Amsterdam, 1105AZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.